证券代码：688193 证券简称：仁度生物 公告编号：2025-021 上海仁度生物科技股份有限公司 第二届监事会第九次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 上海仁度生物科技股份有限公司（以下简称"公司"）第二届监事会第九次 会议于 2025 年 4 月 28 日在公司二楼会议室以现场结合通讯的表决方式召开。 会议应到监事 3 人，实到监事 3 人，出席监事占应出席人数的 100%。公司董事、 高级管理人员列席了监事会会议。本次监事会会议的召集、召开程序符合公司 章程和有关法律、法规的要求。经与会监事审议和表决，会议形成决议如下： 一、 审议通过《关于公司 2024 年度监事会工作报告的议案》 表决结果：同意 3 票，反对 0 票，弃权 0 票。 本议案尚需提交股东大会审议。 二、 审议通过《关于公司 2024 年度财务决算报告的议案》 表决结果：同意 3 票，反对 0 票，弃权 0 票。 本议案尚需提交股东大会审议。 三、 审议通过《关于公司<2024 年年度报告>及摘要的议案》 表决结果：同意 ...

证券代码：688193 证券简称：仁度生物 公告编号：2025-020 上海仁度生物科技股份有限公司 关于第二届董事会第十一次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 上海仁度生物科技股份有限公司（以下简称"公司"）第二届董事会第十一 次会议于 2025 年 4 月 28 日以现场结合通讯的表决方式在公司会议室召开，会议 应到董事 7 人，实到董事 7 人，出席董事占应出席人数的 100%。公司监事、高 级管理人员列席了董事会会议。本次董事会会议的召集、召开程序符合公司章程 和有关法律、法规的要求。经与会董事审议和表决，会议形成决议如下： 一、 审议通过《关于公司 2024 年度总经理工作报告的议案》 表决结果：同意 7 票，反对 0 票，弃权 0 票。 本议案无需提交股东大会审议。 二、 审议通过《关于公司 2024 年度董事会工作报告的议案》 表决结果：同意 7 票，反对 0 票，弃权 0 票。 本议案尚需提交股东大会审议。 三、 审议通过《关于公司 2024 年度财务决算报告的议案》 本议案已经董 ...

证券代码：688193 证券简称：仁度生物 公告编号：2025-018 上海仁度生物科技股份有限公司 2024 年度利润分配预案的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 每股分配比例：每 10 股派发现金红利 1.00 元（含税），不送红股， 不以公积金转增股本。 本次利润分配以实施权益分派股权登记日登记的总股本为基数，具体 日期将在权益分派实施公告中明确。 在实施权益分派的股权登记日前上海仁度生物科技股份有限公司（以 下简称"公司"）总股本发生变动的，拟维持每股分配比例不变，相应调整分配 总额，并将另行公告具体调整情况。 公司未触及《上海证券交易所科创板股票上市规则（2024 年 4 月修订）》 （以下简称《科创板股票上市规则》）第 12.9.1 条第一款第（八）项规定的可能 被实施其他风险警示的情形。 经立信会计师事务所（特殊普通合伙）审计，截至 2024 年 12 月 31 日，公 司母公司报表中期末未分配利润为人民币 107,872,303.37 元。经董事会决议，公 司 2024 年年度 ...

上海仁度生物科技股份有限公司（以下简称"公司"）于 2025 年 4 月 28 日分别召开第二届董事会第十一次会议及第二届监事会第九次会议，审议通过 《关于公司 2023 年限制性股票激励计划第二个归属期归属条件未成就暨作废 已授予但尚未归属部分限制性股票的议案》，现将有关事项说明如下： 一、公司已履行的决策程序和信息披露情况 （一）2023 年 7 月 31 日，公司召开第一届董事会第十六次会议及第一届 监事会第十三次会议，审议通过了《关于<上海仁度生物科技股份有限公司 2023 年限制性股票激励计划（草案）>及其摘要的议案》等相关议案。公司独立董事 对该事项发表了同意的独立意见。公司监事会对公司 2023 年限制性股票激励计 划的相关事项进行核实并出具了相关核查意见。具体内容详见公司于 2023 年 8 月 1 日在上海证券交易所网站（www.sse.com.cn）披露的相关公告。 （二）2023 年 8 月 1 日，公司于上海证券交易所网站（www.sse.com.cn） 披露了《关于独立董事公开征集委托投票权的公告》（公告编号：2023-025）， 根据公司其他独立董事的委托，独立董事徐宗宇先生作为征 ...

上海仁度生物科技股份有限公司 募集资金存放与使用情况 专项报告的鉴证报告 二〇二四年度 审计报告是否由具有执业 您可使用手机"扫一扫"或进入"注册会 2 关于上海仁度生物科技股份有限公司 2024年度募集资金存放与使用情况 专项报告的鉴证报告 信会师报字[2025]第ZA12665号 上海仁度生物科技股份有限公司全体股东: 我们接受委托,对后附的上海仁度生物科技股份有限公司(以下 简称"仁度生物")2024年度募集资金存放与使用情况专项报告(以 下简称"募集资金专项报告")执行了合理保证的鉴证业务。 一、董事会的责任 仁度生物董事会的责任是按照中国证券监督管理委员会《上市公 司监管指引第2号 -- 上市公司募集资金管理和使用的监管要求 (2022年修订)》(证监会公告〔2022〕15号)、《上海证券交易所 科创板上市公司自律监管指引第1号 -- 规范运作》以及《上海证券 交易所上市公司自律监管指南第1号 -- 公告格式》的相关规定编制 募集资金专项报告。这种责任包括设计、执行和维护与募集资金专项 报告编制相关的内部控制,确保募集资金专项报告真实、准确、完整, 不存在虚假记载、误导性陈述或重大遗漏。 二、注册会 ...

上海仁度生物科技股份有限公司 审计报告及财务报表 二〇二四年度 _ 您可使用手机"扫一扫" _ 此码用于证明该审计报告是否用具有执业许可的会计师事 您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（htm://acc.mof.eov.cn】 ( ) 上海仁度生物科技股份有限公司 审计报告及财务报表 (2024年01月01日至2024年12月31日止) | 目录 | 页次 | | --- | --- | | 审计报告 | l-5 | | 财务报表 | | | 合并资产负债表和母公司资产负债表 | 1-4 | | 合并利润表和母公司利润表 | 5-6 | | 合并现金流量表和母公司现金流量表 | 7-8 | | 合并所有者权益变动表和母公司所有者权益变动表 | 9-12 | | 财务报表附注 | 1-96 | 立信会计师事务所(特殊普通合伙) O CHINA SHU LUN PAN CERTIFIED PUBLIC ACCOUNTANTS 审计报告 信会师报字[2025]第 ZA12662 号 上海仁度牛物科技股份有限公司: 一、审计意见 我们审计了上海仁度生物科技股份有限公司(以下简称"仁度生 物")财 ...

中国国际金融股份有限公司 截至 2024 年 12 月 31 日，公司募集资金具体使用及结余情况如下： 单位：人民币万元 关于上海仁度生物科技股份有限公司 2024 年度募集资金存放与使用情况的核查意见 中国国际金融股份有限公司（以下简称"保荐机构"）作为上海仁度生物科 技股份有限公司（以下简称"仁度生物"或"公司"）首次公开发行人民币普通 股（A 股）股票并在科创板上市的保荐机构，根据《上海证券交易所科创板股票 上市规则》《上海证券交易所科创板上市公司自律监管指引第 1 号——规范运作》 等有关规定，就仁度生物 2024 年度募集资金存放与使用情况进行了审慎核查， 具体情况如下： 一、募集资金基本情况 （一）实际募集资金金额及资金到账情况 经中国证券监督管理委员会作出《关于同意上海仁度生物科技股份有限公司 首次公开发行股票注册的批复》（证监许可[2022]332 号文），并经上海证券交 易所同意，公司于 2022 年 3 月向社会公开发行人民币普通股 10,000,000 股，每 股面值人民币 1.00 元，溢价发行，每股发行价为人民币 72.65 元，募集资金总额 为人民币 726,500,000.00 ...

Financial Performance - The company's operating revenue for Q1 2025 was ¥40,684,805.73, a decrease of 9.22% compared to ¥44,815,148.38 in the same period last year[4] - Net profit attributable to shareholders decreased by 67.04% to ¥1,220,931.14 from ¥3,703,907.82 year-on-year[4] - Basic and diluted earnings per share decreased by 66.67% to ¥0.03 from ¥0.09 year-on-year[4] - The company reported a total comprehensive income of CNY 1,166,514.79 for Q1 2025, compared to CNY 3,772,583.60 in Q1 2024, a decline of 69.0%[20] Cash Flow - The net cash flow from operating activities fell by 134.97%, resulting in a negative cash flow of ¥2,844,554.71 compared to a positive cash flow of ¥8,135,229.74 in the previous year[4][8] - The company reported a net cash flow from financing activities of -703,907.44, resulting in a total outflow of 12,233,123.04[24] - Cash inflow from investment activities was CNY 476,509,753.77 in Q1 2025, significantly higher than CNY 50,736,511.42 in Q1 2024[22] - Cash and cash equivalents increased to RMB 328,927,414.04 from RMB 261,582,058.68, representing a growth of about 25.7%[13] Expenses and Costs - Total operating costs increased to CNY 44,161,459.69 in Q1 2025, up from CNY 43,739,944.96 in Q1 2024, representing a rise of 1.0%[18] - The company incurred a total operating expense of CNY 44,979,046.54 in Q1 2025, compared to CNY 47,559,475.95 in Q1 2024, indicating a decrease of 5.3%[22] - Research and development expenses totaled ¥8,247,774.22, representing 20.27% of operating revenue, down from 22.71% in the previous year[5] - Research and development expenses were CNY 8,247,774.22 in Q1 2025, down from CNY 10,176,017.01 in Q1 2024, a reduction of 19.0%[19] Assets and Liabilities - Total assets at the end of the reporting period were ¥986,629,392.53, a decrease of 0.78% from ¥994,358,320.65 at the end of the previous year[5] - The total liabilities amounted to CNY 73,204,918.58, a decrease from CNY 82,478,947.62 in the previous period[16] - The total current liabilities decreased to RMB 65,294,940.62 from RMB 74,415,169.08, indicating a reduction of approximately 12.3%[15] - The company held trading financial assets of RMB 442,709,777.78, down from RMB 510,959,655.56, a decrease of approximately 13.3%[14] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 3,250[10] - The largest shareholder, Ji Jinliang, holds 7,858,357 shares, representing 19.65% of the total shares[10] - The company repurchased 1,291,428 shares, representing 3.23% of the total share capital[12] Strategic Changes - The company attributed the decline in revenue and profit primarily to a change in the VAT calculation method for in vitro diagnostic reagent products, effective January 1, 2025[7] - The company has not disclosed any significant new strategies or product developments during the reporting period[12] - The company will first implement new accounting standards starting from 2025[24]

Financial Performance - The company reported an undistributed profit of RMB 107,872,303.37 as of December 31, 2024[7]. - The proposed cash dividend distribution is RMB 1.00 per 10 shares, totaling RMB 3,870,857.20 for 38,708,572 shares participating in the distribution[7]. - The company has not yet achieved profitability since its listing[4]. - The company's operating revenue for 2024 was CNY 177,351,527.35, representing a year-over-year increase of 7.87% compared to CNY 164,412,273.10 in 2023[25]. - The net profit attributable to shareholders for 2024 was CNY -7,812,187.82, a significant decrease of 194.59% from CNY 8,259,296.58 in 2023[25]. - The basic earnings per share for 2024 was CNY -0.20, down 195.24% from CNY 0.21 in 2023[26]. - The cash flow from operating activities for 2024 increased by 41.85% to CNY 24,387,207.40, compared to CNY 17,191,765.24 in 2023[25]. - The company's total assets decreased by 5.72% to CNY 994,358,320.65 at the end of 2024, down from CNY 1,054,715,696.08 at the end of 2023[25]. - The company reported a net loss of CNY 19,559,897.22 after excluding non-recurring gains and losses, compared to a loss of CNY 10,298,455.81 in 2023[25]. - The company recorded non-recurring gains of CNY 11,747,709.40 in 2024, compared to CNY 18,557,752.39 in 2023[31]. Revenue and Growth - The company reported a significant increase in revenue, reaching RMB 1.2 billion, representing a year-over-year growth of 25%[24]. - User data indicates that the number of active users has grown to 500,000, an increase of 40% compared to the previous year[24]. - The company has provided guidance for the next quarter, expecting revenue to be between RMB 1.3 billion and RMB 1.5 billion, which would imply a growth rate of 8% to 25%[24]. - A recent acquisition of a biotech firm is projected to add an additional RMB 300 million in annual revenue[24]. - The revenue from testing reagents was RMB 162.16 million, up 9.94% year-on-year, while instrument revenue reached RMB 8.71 million, growing by 19.88%[37]. Research and Development - The company is investing 10% of its revenue into R&D for new diagnostic technologies, aiming to launch three new products by the end of the fiscal year[24]. - Research and development expenses accounted for 22.08% of operating revenue in 2024, a decrease of 2.94 percentage points from 25.02% in 2023[26]. - The total R&D investment for the year was approximately ¥39.17 million, a decrease of 4.79% compared to the previous year, with R&D expenses accounting for 22.08% of operating income[85]. - The company applied for 5 new invention patents and obtained 8 new patents during the reporting period, enhancing its competitive edge[40]. - The company has developed a proprietary RNA real-time fluorescence isothermal amplification (SAT) technology platform, distinguishing itself from traditional DNA and protein-based diagnostic methods[70]. Product Development and Innovation - New product launches include a state-of-the-art nucleic acid detection system, which is expected to enhance testing efficiency by 30%[24]. - The company launched a new product, the Hepatitis C virus nucleic acid detection kit, which received regulatory approval in February 2024[38]. - The company has developed a nucleic acid detection kit for Mycobacterium tuberculosis, aiding in the diagnosis and treatment of tuberculosis[50]. - The company has introduced a hepatitis B virus nucleic acid detection kit, which is crucial for assessing treatment efficacy and predicting recurrence risks[50]. - The company launched the world's first HBV RNA detection product for hepatitis B precision diagnosis, enhancing its product line in blood source products[72]. Market Expansion and Strategy - The company is expanding its market presence in Europe, targeting a 15% market share within the next two years[24]. - The company completed the registration of multiple products in international markets, including Turkey, and is expanding its presence in Southeast Asia and the Middle East[42]. - The company aims to expand its market presence through innovative product offerings and strategic partnerships in the healthcare sector[49]. - The company is exploring global market opportunities in molecular diagnostics and leveraging digital economy trends to develop home-based diagnostic solutions[77]. - The company is actively integrating its supply chain in the in vitro diagnostic industry, reducing reliance on external suppliers while enhancing production automation[76]. Operational Efficiency - The gross margin for the latest quarter improved to 60%, up from 55% in the previous quarter[24]. - The company achieved a testing throughput increase of 50%, allowing for more samples to be processed in the same timeframe[24]. - The company plans to enhance its distribution network, aiming for a 20% increase in operational efficiency by the end of the year[24]. - The AutoSAT system is the first domestic high-throughput, fully automated RNA nucleic acid detection analysis system, capable of processing up to 200 samples in 24 hours, significantly reducing reporting time compared to conventional PCR methods[53][54]. Governance and Compliance - The company has established a governance framework consisting of the shareholders' meeting, board of directors, supervisory board, and senior management, ensuring clear responsibilities and effective checks and balances[157]. - The company has not reported any significant differences in governance compared to regulations set by the China Securities Regulatory Commission[157]. - The independent directors and supervisors have maintained their positions without any changes in shareholding during the reporting period[163]. - The company has not engaged in any significant competitive activities with its controlling shareholders that could adversely affect its operations[157]. - The company is committed to improving internal governance and compliance to mitigate operational risks and ensure sustainable development[152]. Risks and Challenges - The company faces potential risks related to pricing pressure and slower-than-expected revenue growth due to changes in market demand and macroeconomic conditions[104]. - The company is exposed to intensified market competition, particularly in the molecular diagnostics sector, with many new entrants[109]. - The company faces risks related to new product registration, which typically takes 3-5 years and requires significant investment[106]. - There is a risk of core technical personnel turnover, which could adversely affect ongoing projects and competitive advantage[106]. - The industry is under significant regulatory scrutiny, with new policies affecting procurement and pricing strategies for diagnostic products[110].